pramipexole Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2233 104632-26-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pramipexole hydrochloride
  • pramipexole hydrochloride hydrate
  • sifrol
  • oprymea
  • pramipexole
  • (S)-Pramipexole
  • mirapexin
  • pramipexole dihydrochloride
  • pramipexole dihydrochloride monohydrate
  • pramipexole HCl
  • pramipexol dihydrobromide
A dopamine agonist that binds with high selectivity and specificity to the D2 subfamily of dopamine receptors of which it has a preferential affinity to D3 receptors, and has full intrinsic activity. Pramipexole alleviates parkinsonian motor deficits by stimulation of dopamine receptors in the striatum. Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover.
  • Molecular weight: 211.33
  • Formula: C10H17N3S
  • CLOGP: 1.17
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 2
  • TPSA: 50.94
  • ALOGS: -3.18
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 90 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.30 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 7 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.85 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 1, 1997 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gambling disorder 429.97 11.46 108 26843 1188 46657923
Impulse-control disorder 337.84 11.46 79 26872 625 46658486
Dyskinesia 308.96 11.46 198 26753 28727 46630384
Compulsive shopping 292.55 11.46 72 26879 723 46658388
Restless legs syndrome 276.32 11.46 149 26802 15694 46643417
Hallucination 214.78 11.46 199 26752 49752 46609359
On and off phenomenon 198.51 11.46 65 26886 1926 46657185
Gambling 160.87 11.46 35 26916 191 46658920
Hallucination, visual 149.09 11.46 105 26846 17768 46641343
Hypersexuality 123.31 11.46 33 26918 473 46658638
Tremor 103.63 11.46 215 26736 115424 46543687
Sudden onset of sleep 101.97 11.46 30 26921 617 46658494
Pleurothotonus 100.08 11.46 34 26917 1131 46657980
Stereotypy 99.93 11.46 27 26924 402 46658709
Obsessive-compulsive disorder 94.03 11.46 43 26908 3172 46655939
Parkinsonism hyperpyrexia syndrome 86.10 11.46 20 26931 153 46658958
Bradykinesia 82.51 11.46 42 26909 3924 46655187
Camptocormia 81.41 11.46 20 26931 199 46658912
Parkinson's disease 80.03 11.46 31 26920 1508 46657603
Dystonia 79.92 11.46 60 26891 11197 46647914
Binge eating 75.02 11.46 21 26930 359 46658752
Muscle rigidity 72.74 11.46 54 26897 9907 46649204
Orthostatic hypotension 68.99 11.46 78 26873 24580 46634531
Stoma site discharge 63.26 11.46 28 26923 1912 46657199
Jealous delusion 61.56 11.46 13 26938 60 46659051
Freezing phenomenon 60.32 11.46 25 26926 1452 46657659
Stoma site erythema 55.47 11.46 22 26929 1140 46657971
Fall 53.70 11.46 349 26602 328748 46330363
Delusion 50.80 11.46 46 26905 11142 46647969
Stoma site pain 49.99 11.46 20 26931 1060 46658051
Torticollis 49.69 11.46 23 26928 1744 46657367
Therapeutic response shortened 49.13 11.46 33 26918 5166 46653945
Neuroleptic malignant syndrome 49.07 11.46 45 26906 11077 46648034
Compulsive hoarding 48.72 11.46 11 26940 73 46659038
Drug dispensed to wrong patient 46.79 11.46 13 26938 216 46658895
Rheumatoid arthritis 43.19 11.46 45 26906 240170 46418941
Hyperkinesia 43.04 11.46 21 26930 1791 46657320
Parkinsonism 42.77 11.46 36 26915 7912 46651199
Somnolence 42.51 11.46 191 26760 156330 46502781
Gait disturbance 39.24 11.46 177 26774 145086 46514025
Sleep attacks 38.61 11.46 9 26942 70 46659041
Acute psychosis 38.28 11.46 20 26931 1972 46657139
Confusional state 37.50 11.46 187 26764 159705 46499406
Abnormal behaviour 35.76 11.46 52 26899 21006 46638105
Psychomotor hyperactivity 35.02 11.46 35 26916 9578 46649533
Akinesia 34.37 11.46 18 26933 1783 46657328
Contraindicated product administered 32.40 11.46 4 26947 79943 46579168
Pituitary haemorrhage 32.26 11.46 8 26943 83 46659028
Dopamine dysregulation syndrome 31.56 11.46 10 26941 266 46658845
Abnormal dreams 31.30 11.46 34 26917 10245 46648866
Febrile neutropenia 31.30 11.46 8 26943 94619 46564492
Malignant polyp 30.50 11.46 9 26942 187 46658924
Economic problem 29.72 11.46 17 26934 2003 46657108
Delirium 29.58 11.46 66 26885 37162 46621949
Diabetes mellitus inadequate control 29.07 11.46 37 26914 13177 46645934
Neutropenia 29.05 11.46 24 26927 143180 46515931
Psychotic disorder 28.88 11.46 49 26902 22572 46636539
Dependence 27.74 11.46 16 26935 1915 46657196
Hyperphagia 27.67 11.46 15 26936 1593 46657518
Medication error 27.07 11.46 57 26894 30854 46628257
Systemic lupus erythematosus 27.06 11.46 3 26948 65177 46593934
Maternal exposure during pregnancy 26.53 11.46 13 26938 102536 46556575
Vestibular migraine 26.17 11.46 7 26944 100 46659011
Memory impairment 26.16 11.46 101 26850 77236 46581875
Posture abnormal 25.88 11.46 16 26935 2174 46656937
Dropped head syndrome 25.27 11.46 7 26944 115 46658996
Malignant neoplasm progression 24.55 11.46 4 26947 64922 46594189
Crime 24.25 11.46 5 26946 20 46659091
Stoma site infection 23.95 11.46 11 26940 819 46658292
Orthostatic intolerance 23.36 11.46 12 26939 1142 46657969
Multiple drug therapy 22.97 11.46 11 26940 900 46658211
Fibroma 22.77 11.46 11 26940 918 46658193
Joint swelling 22.77 11.46 38 26913 166035 46493076
Anxiety 22.10 11.46 180 26771 181777 46477334
Compulsions 21.65 11.46 7 26944 199 46658912
Movement disorder 20.85 11.46 36 26915 16813 46642298
Chorea 20.64 11.46 11 26940 1129 46657982
Heat stroke 20.35 11.46 9 26942 613 46658498
Pancytopenia 20.22 11.46 12 26939 85046 46574065
Restlessness 19.99 11.46 45 26906 25479 46633632
Nightmare 19.94 11.46 35 26916 16563 46642548
Female orgasmic disorder 19.90 11.46 5 26946 55 46659056
Inhibitory drug interaction 19.66 11.46 13 26938 1982 46657129
Treatment failure 19.62 11.46 15 26936 93072 46566039
Meningorrhagia 19.56 11.46 6 26945 143 46658968
Hyperventilation 19.55 11.46 20 26931 5627 46653484
Coronary artery dissection 19.46 11.46 9 26942 681 46658430
Diarrhoea 18.73 11.46 220 26731 559382 46099729
Catecholamines urine increased 18.68 11.46 4 26947 20 46659091
Sleep apnoea syndrome 18.36 11.46 40 26911 22161 46636950
Speech disorder 18.21 11.46 54 26897 36113 46622998
Bulimia nervosa 18.20 11.46 8 26943 537 46658574
Narcolepsy 17.72 11.46 10 26941 1149 46657962
Toxicity to various agents 17.55 11.46 63 26888 211703 46447408
Orgasm abnormal 17.42 11.46 5 26946 94 46659017
Vaccination site oedema 16.74 11.46 4 26947 35 46659076
Vaccination site pruritus 16.64 11.46 4 26947 36 46659075
Vaccination site bruising 16.64 11.46 4 26947 36 46659075
Drug intolerance 16.39 11.46 38 26913 147011 46512100
Product substitution issue 15.90 11.46 30 26921 15001 46644110
Drug withdrawal syndrome 15.85 11.46 43 26908 27341 46631770
Bronchopulmonary aspergillosis allergic 15.81 11.46 8 26943 738 46658373
Stoma site irritation 15.81 11.46 6 26945 276 46658835
Compulsive sexual behaviour 15.60 11.46 4 26947 48 46659063
Snoring 15.32 11.46 14 26937 3428 46655683
Hypercapnia 15.32 11.46 16 26935 4610 46654501
Oedema peripheral 15.27 11.46 150 26801 159556 46499555
Depressed mood 15.15 11.46 48 26903 33271 46625840
Lung opacity 14.89 11.46 9 26942 1175 46657936
Rash 14.84 11.46 133 26818 356379 46302732
Balance disorder 14.77 11.46 75 26876 64446 46594665
Vaccination site pain 14.71 11.46 4 26947 61 46659050
Reduced facial expression 14.64 11.46 9 26942 1211 46657900
Exposure during pregnancy 14.60 11.46 25 26926 108187 46550924
Vaccination site erythema 14.25 11.46 4 26947 69 46659042
Suspiciousness 14.18 11.46 6 26945 367 46658744
Drug hypersensitivity 13.98 11.46 83 26868 243742 46415369
Thrombocytopenia 13.87 11.46 33 26918 126548 46532563
Hypokinesia 13.76 11.46 24 26927 11298 46647813
Pre-existing condition improved 13.74 11.46 18 26933 6594 46652517
Tardive dyskinesia 13.35 11.46 19 26932 7524 46651587
Kleptomania 13.15 11.46 3 26948 21 46659090
Withdrawal syndrome 13.13 11.46 31 26920 18103 46641008
Erysipelas 13.06 11.46 18 26933 6920 46652191
Therapeutic product effect variable 13.02 11.46 8 26943 1075 46658036
Amnesia 12.97 11.46 53 26898 41578 46617533
Total lung capacity decreased 12.84 11.46 8 26943 1101 46658010
Drug interaction 12.81 11.46 176 26775 202918 46456193
Eating disorder 12.80 11.46 27 26924 14627 46644484
Anisomastia 12.80 11.46 3 26948 24 46659087
Libido increased 12.73 11.46 7 26944 765 46658346
Segmented hyalinising vasculitis 12.69 11.46 3 26948 25 46659086
Middle insomnia 12.66 11.46 21 26930 9494 46649617
Insomnia 12.55 11.46 148 26803 164776 46494335
Product administration error 12.51 11.46 32 26919 19649 46639462
Parkinsonian gait 12.48 11.46 6 26945 495 46658616
Blood pressure inadequately controlled 12.42 11.46 14 26937 4392 46654719
Disease progression 12.40 11.46 21 26930 91279 46567832
Dizziness 12.39 11.46 270 26681 340144 46318967
Agitation 12.39 11.46 64 26887 55351 46603760
Initial insomnia 12.30 11.46 14 26937 4438 46654673
Stoma site candida 12.02 11.46 3 26948 32 46659079
Muscle atrophy 11.98 11.46 16 26935 5968 46653143
Skull fracture 11.83 11.46 7 26944 879 46658232
Mucosal inflammation 11.60 11.46 4 26947 38972 46620139

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gambling disorder 692.02 13.55 169 16880 1671 29933758
Impulse-control disorder 679.85 13.55 158 16891 1237 29934192
Hypersexuality 591.97 13.55 143 16906 1344 29934085
Hallucination 363.16 13.55 266 16783 48793 29886636
Dyskinesia 272.21 13.55 164 16885 21670 29913759
Restless legs syndrome 228.31 13.55 100 16949 6772 29928657
Dopamine dysregulation syndrome 206.08 13.55 50 16999 478 29934951
Compulsive shopping 203.73 13.55 48 17001 400 29935029
Gambling 188.89 13.55 40 17009 191 29935238
On and off phenomenon 161.13 13.55 61 16988 2830 29932599
Hallucination, visual 153.13 13.55 102 16947 16011 29919418
Stereotypy 144.85 13.55 38 17011 510 29934919
Obsessive-compulsive disorder 114.42 13.55 53 16996 4088 29931341
Paraphilia 103.83 13.55 21 17028 76 29935353
Libido increased 98.69 13.55 31 17018 813 29934616
Delusion 95.27 13.55 68 16981 11921 29923508
Sudden onset of sleep 94.11 13.55 26 17023 429 29935000
Jealous delusion 82.20 13.55 21 17028 252 29935177
Parkinson's disease 76.98 13.55 31 17018 1697 29933732
Gait disturbance 70.73 13.55 141 16908 74636 29860793
Freezing phenomenon 70.25 13.55 30 17019 1906 29933523
Psychomotor hyperactivity 68.46 13.55 48 17001 8176 29927253
Abnormal behaviour 67.49 13.55 78 16971 25545 29909884
Muscle rigidity 61.12 13.55 49 17000 10212 29925217
Parkinsonism hyperpyrexia syndrome 60.03 13.55 14 17035 111 29935318
Binge eating 59.47 13.55 13 17036 74 29935355
Fall 56.00 13.55 228 16821 181644 29753785
Psychotic disorder 50.88 13.55 62 16987 21453 29913976
Impulsive behaviour 50.72 13.55 24 17025 1941 29933488
Tremor 50.72 13.55 124 16925 75239 29860190
Agitation 49.94 13.55 101 16948 53972 29881457
Aggression 49.43 13.55 81 16968 36826 29898603
Dependence 47.82 13.55 20 17029 1206 29934223
Bradykinesia 47.40 13.55 27 17022 3203 29932226
Compulsive hoarding 46.57 13.55 9 17040 24 29935405
Hyperkinesia 46.24 13.55 23 17026 2075 29933354
Compulsive sexual behaviour 45.84 13.55 13 17036 237 29935192
Confusional state 45.45 13.55 174 16875 134660 29800769
Sleep attacks 45.27 13.55 12 17037 168 29935261
Neuroleptic malignant syndrome 45.26 13.55 51 16998 16244 29919185
Economic problem 44.50 13.55 20 17029 1437 29933992
Hyperphagia 42.93 13.55 19 17030 1316 29934113
Toxicity to various agents 42.57 13.55 24 17025 177159 29758270
Insomnia 42.36 13.55 133 16916 93203 29842226
Mania 40.77 13.55 37 17012 9117 29926312
Dystonia 40.76 13.55 38 17011 9689 29925740
Voyeurism 38.70 13.55 7 17042 11 29935418
Somnolence 38.63 13.55 132 16917 96631 29838798
Personality change 36.32 13.55 26 17023 4574 29930855
Excessive masturbation 35.38 13.55 9 17040 106 29935323
Delirium 35.27 13.55 74 16975 40557 29894872
Stoma site erythema 34.03 13.55 15 17034 1029 29934400
Sexually inappropriate behaviour 33.64 13.55 11 17038 329 29935100
Restlessness 33.55 13.55 52 16997 22547 29912882
Dropped head syndrome 33.40 13.55 8 17041 72 29935357
Pyrexia 33.38 13.55 74 16975 294415 29641014
Suspiciousness 32.19 13.55 11 17038 378 29935051
Neutropenia 31.45 13.55 17 17032 128523 29806906
Posture abnormal 31.23 13.55 17 17032 1847 29933582
Acute psychosis 31.12 13.55 17 17032 1859 29933570
Febrile neutropenia 31.01 13.55 11 17038 106682 29828747
Anticholinergic syndrome 30.66 13.55 13 17036 811 29934618
Paranoia 30.20 13.55 33 17016 10155 29925274
Road traffic accident 29.23 13.55 42 17007 17029 29918400
Akinesia 29.11 13.55 18 17031 2482 29932947
Stoma site discharge 28.84 13.55 15 17034 1486 29933943
Diarrhoea 28.81 13.55 96 16953 334007 29601422
Sopor 28.15 13.55 33 17016 10958 29924471
Hypervigilance 28.05 13.55 8 17041 149 29935280
Obsessive-compulsive personality disorder 27.06 13.55 8 17041 170 29935259
Therapeutic product effect variable 27.03 13.55 14 17035 1375 29934054
Sleep apnoea syndrome 26.73 13.55 40 17009 16817 29918612
Compulsions 26.46 13.55 8 17041 184 29935245
Dementia 26.40 13.55 34 17015 12427 29923002
Hypomania 25.65 13.55 16 17033 2240 29933189
Stoma site pain 25.63 13.55 11 17038 707 29934722
Human ehrlichiosis 25.60 13.55 8 17041 206 29935223
Contraindicated product prescribed 25.52 13.55 9 17040 340 29935089
Acute kidney injury 25.47 13.55 76 16973 273766 29661663
Spontaneous penile erection 25.24 13.55 8 17041 216 29935213
Somnambulism 24.99 13.55 18 17031 3196 29932233
Dysarthria 24.69 13.55 54 16995 30436 29904993
Platelet count decreased 24.57 13.55 15 17034 106114 29829315
Condition aggravated 24.52 13.55 148 16901 137718 29797711
Pancytopenia 24.32 13.55 9 17040 85043 29850386
Hallucination, tactile 23.13 13.55 8 17041 285 29935144
Sleep-related eating disorder 22.95 13.55 8 17041 292 29935137
Depression 22.86 13.55 107 16942 90330 29845099
Suicidal ideation 22.76 13.55 58 16991 36056 29899373
Motor dysfunction 22.71 13.55 22 17027 5880 29929549
Inappropriate antidiuretic hormone secretion 22.39 13.55 30 17019 11392 29924037
Sexual activity increased 21.98 13.55 5 17044 35 29935394
Testicular necrosis 21.50 13.55 4 17045 8 29935421
Eosinophilic fasciitis 21.49 13.55 6 17043 103 29935326
Rapid eye movements sleep abnormal 21.45 13.55 7 17042 208 29935221
Dysstasia 21.22 13.55 28 17021 10477 29924952
Memory impairment 20.68 13.55 57 16992 37117 29898312
Parkinsonism 20.60 13.55 23 17026 7246 29928183
Sleep disorder 20.56 13.55 44 17005 24435 29910994
Food interaction 20.50 13.55 10 17039 865 29934564
Encephalitis toxic 20.22 13.55 6 17043 129 29935300
Disinhibition 20.06 13.55 13 17036 1944 29933485
Disturbance in attention 20.01 13.55 41 17008 22088 29913341
Depressive symptom 19.55 13.55 12 17037 1633 29933796
Movement disorder 19.44 13.55 26 17023 9857 29925572
Delusional disorder, jealous type 19.42 13.55 3 17046 0 29935429
Balance disorder 19.36 13.55 55 16994 36438 29898991
Therapeutic response shortened 18.94 13.55 16 17033 3584 29931845
Marital problem 18.73 13.55 5 17044 72 29935357
Rash 18.73 13.55 52 16997 191837 29743592
Torticollis 18.55 13.55 10 17039 1065 29934364
Bipolar I disorder 18.22 13.55 9 17040 800 29934629
Dizziness 18.19 13.55 180 16869 194729 29740700
Verbal abuse 18.11 13.55 6 17043 187 29935242
Pyroglutamic acidosis 17.19 13.55 5 17044 100 29935329
Sepsis 17.18 13.55 36 17013 146359 29789070
Gait inability 17.14 13.55 35 17014 18806 29916623
Malignant neoplasm progression 17.03 13.55 10 17039 72277 29863152
Withdrawal syndrome 16.85 13.55 26 17023 11224 29924205
Cardiac arrest 16.61 13.55 17 17032 92833 29842596
Product use in unapproved indication 16.25 13.55 11 17038 73682 29861747
Pleurothotonus 16.23 13.55 9 17040 1014 29934415
Paedophilia 16.12 13.55 3 17046 6 29935423
Reduced facial expression 15.58 13.55 8 17041 772 29934657
Nightmare 15.48 13.55 26 17023 12050 29923379
Intentional medical device removal by patient 14.89 13.55 6 17043 329 29935100
Excessive exercise 14.80 13.55 3 17046 11 29935418
Device kink 14.77 13.55 7 17042 568 29934861
Anxiety 14.40 13.55 94 16955 89777 29845652
Device dislocation 14.40 13.55 16 17033 5015 29930414
Hyperkalaemia 14.36 13.55 10 17039 66000 29869429
White blood cell count decreased 14.31 13.55 16 17033 83931 29851498
Oedema peripheral 14.20 13.55 106 16943 105726 29829703
Needle fatigue 13.62 13.55 4 17045 83 29935346
IVth nerve paresis 13.59 13.55 3 17046 18 29935411
Micturition disorder 13.57 13.55 10 17039 1839 29933590

Pharmacologic Action:

SourceCodeDescription
ATC N04BC05 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopamine agonists
FDA MoA N0000000117 Dopamine Agonists
FDA EPC N0000175768 Nonergot Dopamine Agonist
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000975 Antioxidants
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018491 Dopamine Agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:48578 free-radical scavenger
CHEBI has role CHEBI:51065 agonista dopaminergico
CHEBI has role CHEBI:66956 antidyskinetic drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Restless legs indication 32914008 DOID:0050425
Parkinson's disease indication 49049000 DOID:14330
Fibromyalgia off-label use 203082005 DOID:631
Hallucinations contraindication 7011001
Dyskinesia contraindication 9748009
Orthostatic hypotension contraindication 28651003
Narcolepsy contraindication 60380001 DOID:8986
Psychotic disorder contraindication 69322001
Sleep apnea contraindication 73430006 DOID:0050847
Kidney disease contraindication 90708001 DOID:557
Drowsy contraindication 271782001
Malignant melanoma contraindication 372244006
Breastfeeding (mother) contraindication 413712001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.57 Basic
pKa2 5.18 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR AGONIST EC50 6.60 WOMBAT-PK CHEMBL
D(4) dopamine receptor GPCR AGONIST Ki 9.31 CHEMBL
D(3) dopamine receptor GPCR AGONIST EC50 8.67 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 6.20 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 6.16 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.28 PDSP
Alpha-2A adrenergic receptor GPCR Ki 7.12 PDSP
5-hydroxytryptamine receptor 7 GPCR Ki 5.93 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 5.78 PDSP
Histamine H2 receptor GPCR Ki 5.57 PDSP
5-hydroxytryptamine receptor 1B GPCR Ki 5.45 PDSP
D(2) dopamine receptor GPCR Kd 8.80 CHEMBL
D(3) dopamine receptor GPCR Ki 9.35 CHEMBL
D(2) dopamine receptor GPCR Ki 8.51 CHEMBL

External reference:

IDSource
4024071 VUID
N0000022076 NUI
D00559 KEGG_DRUG
191217-81-9 SECONDARY_CAS_RN
4021042 VANDF
4024071 VANDF
C0721754 UMLSCUI
CHEBI:8356 CHEBI
G6L PDB_CHEM_ID
119570 PUBCHEM_CID
CHEMBL301265 ChEMBL_ID
CHEMBL542257 ChEMBL_ID
CHEMBL3182733 ChEMBL_ID
D000077487 MESH_DESCRIPTOR_UI
DB00413 DRUGBANK_ID
953 IUPHAR_LIGAND_ID
6227 INN_ID
83619PEU5T UNII
236747 RXNORM
169631 MMSL
23370 MMSL
5340 MMSL
d04145 MMSL
006721 NDDF
006722 NDDF
108471007 SNOMEDCT_US
386852009 SNOMEDCT_US
412282004 SNOMEDCT_US
725650009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Mirapex HUMAN PRESCRIPTION DRUG LABEL 1 0597-0101 TABLET 0.75 mg ORAL NDA 27 sections
Mirapex ER HUMAN PRESCRIPTION DRUG LABEL 1 0597-0109 TABLET, EXTENDED RELEASE 0.38 mg ORAL NDA 31 sections
Mirapex ER HUMAN PRESCRIPTION DRUG LABEL 1 0597-0113 TABLET, EXTENDED RELEASE 1.50 mg ORAL NDA 31 sections
Mirapex ER HUMAN PRESCRIPTION DRUG LABEL 1 0597-0115 TABLET, EXTENDED RELEASE 3 mg ORAL NDA 31 sections
Mirapex ER HUMAN PRESCRIPTION DRUG LABEL 1 0597-0116 TABLET, EXTENDED RELEASE 4.50 mg ORAL NDA 31 sections
Mirapex HUMAN PRESCRIPTION DRUG LABEL 1 0597-0183 TABLET 0.13 mg ORAL NDA 27 sections
Mirapex HUMAN PRESCRIPTION DRUG LABEL 1 0597-0184 TABLET 0.25 mg ORAL NDA 27 sections
Mirapex HUMAN PRESCRIPTION DRUG LABEL 1 0597-0185 TABLET 0.50 mg ORAL NDA 27 sections
Mirapex HUMAN PRESCRIPTION DRUG LABEL 1 0597-0190 TABLET 1 mg ORAL NDA 27 sections
Mirapex HUMAN PRESCRIPTION DRUG LABEL 1 0597-0191 TABLET 1.50 mg ORAL NDA 27 sections
Mirapex ER HUMAN PRESCRIPTION DRUG LABEL 1 0597-0285 TABLET, EXTENDED RELEASE 0.75 mg ORAL NDA 31 sections
Mirapex ER HUMAN PRESCRIPTION DRUG LABEL 1 0597-0286 TABLET, EXTENDED RELEASE 2.25 mg ORAL NDA 31 sections
Mirapex ER HUMAN PRESCRIPTION DRUG LABEL 1 0597-0287 TABLET, EXTENDED RELEASE 3.75 mg ORAL NDA 31 sections
Pramipexole Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-7597 TABLET 1 mg ORAL ANDA 28 sections
Pramipexole Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6704 TABLET 0.25 mg ORAL ANDA 20 sections
Pramipexole DihydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-251 TABLET, EXTENDED RELEASE 0.38 mg ORAL ANDA 28 sections
Pramipexole DihydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-252 TABLET, EXTENDED RELEASE 0.75 mg ORAL ANDA 28 sections
Pramipexole DihydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-253 TABLET, EXTENDED RELEASE 1.50 mg ORAL ANDA 28 sections
Pramipexole DihydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-254 TABLET, EXTENDED RELEASE 3 mg ORAL ANDA 28 sections
Pramipexole DihydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-255 TABLET, EXTENDED RELEASE 4.50 mg ORAL ANDA 28 sections
Pramipexole DihydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-305 TABLET, EXTENDED RELEASE 2.25 mg ORAL ANDA 28 sections
Pramipexole DihydrochlorideExtended-Release HUMAN PRESCRIPTION DRUG LABEL 1 10370-306 TABLET, EXTENDED RELEASE 3.75 mg ORAL ANDA 28 sections
Pramipexole Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-091 TABLET 0.13 mg ORAL ANDA 20 sections
Pramipexole Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-092 TABLET 0.25 mg ORAL ANDA 20 sections
Pramipexole Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-093 TABLET 0.50 mg ORAL ANDA 20 sections
Pramipexole Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-094 TABLET 1 mg ORAL ANDA 20 sections
Pramipexole Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-095 TABLET 1.50 mg ORAL ANDA 20 sections
Pramipexole Dihydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 13668-184 TABLET 0.75 mg ORAL ANDA 20 sections
PRAMIPEXOLE DIHYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-409 TABLET 0.50 mg ORAL ANDA 28 sections
Pramipexole Dihydrochloride Human Prescription Drug Label 1 16714-916 TABLET, EXTENDED RELEASE 0.38 mg ORAL ANDA 26 sections